Study Summary
This trial will test if a new combination therapy of ribociclib and ET is effective and safe in treating patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
- Hormone Receptor-positive Breast Cancer
- erbB-2 Receptor
- Locoregional Recurrence
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 3 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Investigational Group
1 of 1
Experimental Treatment
200 Total Participants · 1 Treatment Group
Primary Treatment: Investigational Group · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 16th, 2021
Last Reviewed: November 20th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.